Anebulo Pharmaceuticals Administers First Doses in Selonabant Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 25 2025
0mins
Phase 1 Study Initiation: Anebulo Pharmaceuticals has commenced its Phase 1 single ascending dose study of intravenous selonabant in healthy young adults.
Funding Support: The study is being supported by a collaborative grant from the National Institute on Drug Abuse.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
